miR-181b functions as an oncomiR in colorectal cancer by targeting PDCD4

Yanqing Liu, Uzair-ur-Rehman, Yu Guo, Hongwei Liang, Rongjie Cheng, Fei Yang, Yeting Hong, Chihao Zhao, Minghui Liu, Mengchao Yu, Xinyan Zhou, Kai Yin, Jiangning Chen, Junfeng Zhang, Chen-Yu Zhang, Feng Zhi, Xi Chen

1 State Key Laboratory of Pharmaceutical Biotechnology, Collaborative Innovation Center of Chemistry for Life Sciences, Jiangsu Engineering Research Center for MicroRNA Biology and Biotechnology, NJU Advanced Institute for Life Sciences (NAILS), School of Life Sciences, Nanjing University, 163 Xianlin Road, Nanjing 210046, China
2 Modern Medical Research Center, Third Affiliated Hospital of Soochow University, 185 Juqian Road, Changzhou 213003, China
3 Department of Gastrointestinal Surgery, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, 321 Zhongshan Road, Nanjing 210008, China

Correspondence: cyzhang@nju.edu.cn (C.-Y. Zhang), danielzhif@163.com (F. Zhi), xichen@nju.edu.cn (X. Chen)

ABSTRACT

Programmed cell death 4 (PDCD4) is a RNA-binding protein that acts as a tumor suppressor in many cancer types, including colorectal cancer (CRC). During CRC carcinogenesis, PDCD4 protein levels remarkably decrease, but the underlying molecular mechanism for decreased PDCD4 expression is not fully understood. In this study, we performed bioinformatics analysis to identify miRNAs that potentially target PDCD4. We demonstrated miR-181b as a direct regulator of PDCD4. We further showed that activation of IL6/STAT3 signaling pathway increased miR-181b expression and consequently resulted in downregulation of PDCD4 in CRC cells. In addition, we investigated the biological effects of PDCD4 inhibition by miR-181b both in vitro and in vivo and found that miR-181b could promote cell proliferation and migration and suppress apoptosis in CRC cells and accelerate tumor growth in xenograft mice, potentially through targeting PDCD4. Taken together, this study highlights an oncomiR role for miR-181b in regulating PDCD4 in CRC and suggests that miR-181b may be a novel molecular therapeutic target for CRC.

KEYWORDS microRNA, colorectal cancer, miR-181b, PDCD4

INTRODUCTION

Colorectal cancer (CRC) is a major worldwide health problem due to its high prevalence and mortality rate. In the USA, CRC is currently the third most common cancer type and the third leading cause of cancer-related death (Siegel et al., 2015). Although there has been a recent increase in the understanding, diagnosis and treatment of CRC, the exact mechanisms contributing to the origin and development of CRC remain complex and unclear.

In general, CRC results from an accumulation of genetic and epigenetic changes in colon epithelial cells. Among the myriad causes of CRC, oncogene activation (e.g., KRAS and IGF1R) and tumor suppressor gene silencing (e.g., APC and RET) play vital roles during tumorigenesis (Downward, 2003; Luo et al., 2013; Su et al., 2014; Dow et al., 2015). In recent years, programmed cell death 4 (PDCD4) has received considerable attention as a tumor suppressor protein (Biyanee et al., 2015). PDCD4 is a nuclear-cytoplasmic shuttling and RNA-binding protein involved in controlling the translation of specific mRNAs. Recent findings indicate that PDCD4 can function as a protein translation suppressor though both eIF4A-dependent or -independent pathways (Yang et al., 2003; Yang et al., 2004; Singh et al., 2011; Wedeken et al., 2011). PDCD4 is widely recognized as an important tumor suppressor, as its expression is dramatically
downregulated in many cancer types, including CRC (Yang et al., 2006), lung cancer (Chen et al., 2003), breast cancer (Gonzalez-Villasana et al., 2012) and gastric cancer (Guo et al., 2013). Several studies have validated that loss of PDCD4 during tumorigenesis promotes cancer cell proliferation (Li et al., 2014), metastasis (Yang et al., 2006) and inhibits apoptosis (Wang et al., 2010b). Although our knowledge about PDCD4 has quickly increased in recent years, there is still much work to be done to elucidate how PDCD4 expression is regulated during carcinogenesis.

MicroRNAs (miRNAs) are small (19–23 nucleotides) non-coding RNA molecules (He and Hannon, 2004). In general, miRNAs act as endogenous suppressors of gene expression by binding to the 3′-untranslated region (3′-UTR) of target mRNAs to induce translational repression or mRNA cleavage (Bushati and Cohen, 2007). Since their discovery, miRNAs have gained attention as post-transcriptional regulators in many biological processes, including cancer (Esquela-Kerscher and Slack, 2006). Years of continued research on miRNAs have revealed that many miRNAs directly correlate with human cancers and that these miRNAs can function as tumor suppressor miRNAs or oncomiRs (Esquela-Kerscher and Slack, 2006). Abnormal miRNA expression also plays a pivotal role during CRC initiation, and some miRNAs directly regulate CRC cell proliferation, invasion and apoptosis. Among the miRNAs correlated with tumorigenesis, miR-181b is one of the most important. miR-181b was reported to be significantly upregulated in CRC (Nakajima et al., 2006; Xi et al., 2006; Schetter et al., 2008; Degagne et al., 2014; Liu et al., 2014) and is associated with the poor prognosis of CRC patients (Schetter et al., 2008), indicating that miR-181b may be involved in the pathogenesis of CRC as an oncogene. Conversely, miR-181b has been found to be frequently downregulated in CRC samples due to higher hypermethylation and exert tumor-suppressive effects (Zhao et al., 2016). Thus, whether miR-181b functions as an oncogene or a tumor suppressor is dependent on the cell and tumor types, and miR-181b may exert different functions under different circumstances. Overall the findings of ours and others highlight distinguishing characteristics of miR-181b in both promoting and suppressing colorectal tumorigenesis. Thus, the molecular mechanism underlying the contribution of miR-181b to CRC development and progression needs to be fully elucidated.

STAT3, a transcription factor activated by IL-6, is closely associated with CRC (Monkawara et al., 2011; Pradhan et al., 2012; Waldner et al., 2012). Increased IL-6 expression has been correlated with advanced disease stage and decreased survival of CRC patients, and several therapeutics targeting the IL6/STAT3 signaling pathway have been developed as a promising strategy for treatment of CRC (Waldner et al., 2012). It is important to note that a large part of the functions of IL-6/STAT3 pathway resulted from their abilities to regulate downstream miRNAs (Iliopoulos et al., 2010; Degagne et al., 2014). One interesting example is that STAT3 directly activates transcription of miR-21 and miR-181b during the transformation process (Iliopoulos et al., 2010). Thus, investigating the functions of the downstream miRNAs of the IL6/STAT3 signaling pathway may contribute to our understanding of the molecular mechanisms underlying CRC development.

Although PDCD4, miR-181b and IL6/STAT3 signaling pathway are tightly associated with CRC carcinogenesis, it is necessary to explore their relationship and uncover the regulatory network constituted by them. In this study, we found that miR-181b, as an IL-6/STAT3-activated miRNA, directly targets PDCD4 to promote CRC cell proliferation and migration and to inhibit apoptosis in vitro and accelerate tumor growth in vivo.

RESULTS
CRC tissues exhibit downregulation of PDCD4 protein but not mRNA

We first examined PDCD4 expression patterns in human CRC tissues. After measuring PDCD4 protein levels in 14 pairs of CRC tissues and normal adjacent tissues, we found that PDCD4 protein levels were dramatically decreased in CRC tissues compared to normal adjacent tissues (Fig. 1A and 1B). We then measured PDCD4 mRNA levels in the same CRC tissue pairs and detected irregular alterations in PDCD4 mRNA levels between the tumor and paired non-tumor tissues (Fig. 1C). The inconsistency between PDCD4 protein and mRNA expression in CRC tissues suggests that PDCD4 expression is regulated through a post-transcriptional mechanism.

Identification of PDCD4 as a miR-181b target

Because miRNA is an important and widely existing way to post-transcriptionally regulate gene expression, we hypothesized that some miRNAs regulated PDCD4 protein level in CRC. We used a bioinformatics software Targetscan to predict potential miRNAs that target PDCD4. We identified miRNAs in the miR-181 family as the top candidates. There are four miR-181 family members (miR-181a/b/c/d) encoded by three independent transcripts on three separate chromosomes. Among them, human miR-181a/b have more gene copies (Ji et al., 2009) and higher expression levels (Landgraf et al., 2007) than miR-181c/d. In addition, miR-181a/b have been more closely implicated in cancer than miR-181c/d, and have thus received more attention in the miRNA field (Mansueto et al., 2010; Wang et al., 2010a; Liu et al., 2014; Parikh et al., 2014). For miR-181a/b, the minimum free energy value of the hybrid between miR-181b and the conserved binding site on the PDCD4 3′-UTR is -17.4 kcal/mol and is lower than that of miR-181a (~16.2 kcal/mol), suggesting that miR-181b may bind more tightly to PDCD4 3′-UTR than miR-181a. Thus, we used miR-181b for further experimentation. The predicted interaction between miR-181b and PDCD4 3′-UTR is illustrated in Fig. 2A. There was
perfect base-pairing between the seed region (the core sequence that encompasses the first 2–8 bases of the mature miRNA) and the cognate target, and the miR-181b binding sequence in the PDCD4 3′-UTR was highly conserved across species (Fig. 2A).

We next examined whether miR-181b expression levels inversely correlated with PDCD4 expression in CRC tissues. We measured miR-181b levels in the same 14 pairs of CRC tissues and corresponding normal tissues and found that the miR-181b levels were consistently higher in CRC tissues (Fig. 2B), which was consistent with the idea that miRNA levels are inversely correlated to the levels of their targets. We further illustrated the inverse correlation between miR-181b and PDCD4 protein levels (Fig. 2C) and the disparity between the miR-181b and PDCD4 mRNA levels (Fig. 2D) using Pearson’s correlation scatter plots. Therefore, we considered PDCD4 to be a miR-181b target based on computational prediction and the inverse correlation between miR-181b and PDCD4 protein levels in human CRC tissues.

**miR-181b directly regulates PDCD4 expression at the post-transcriptional level**

We further examined the inverse correlation between miR-181b and PDCD4 by evaluating PDCD4 expression levels in human CRC cells after miR-181b overexpression or knockdown. Fig. 3A demonstrates efficient miR-181b overexpression or knockdown in SW480 cells. As anticipated, PDCD4 protein expression significantly decreased upon miR-181b overexpression, whereas treatment with the miR-181b inhibitor increased PDCD4 protein levels in SW480 cells (Fig. 3B and 3C). We also examined PDCD4 mRNA expression after transfection. miR-181b overexpression or knockdown only slightly affected PDCD4 mRNA levels (Fig. 3D). To demonstrate the robustness of the test, we repeated the above experiments in two other CRC cell lines (Caco2 and HT29) and observed consistent results (Fig. 3A–D).

To determine whether miR-181b suppresses PDCD4 expression through direct interaction with the binding site in the PDCD4 3′-UTR, we fused the PDCD4 3′-UTR sequence containing the presumed miR-181b binding site into the downstream region of the firefly luciferase gene in a reporter plasmid. We transfected the resulting plasmid into SW480 cells along with the miR-181b mimic, miR-181b inhibitor or scrambled negative control RNAs. As expected, miR-181b overexpression resulted in an approximately 70% reduction in luciferase reporter activity compared to cells transfected with control mimic, whereas miR-181b inhibition resulted in a 30% increase in reporter activity compared to cells transfected with the control inhibitor (Fig. 3E). We next constructed a mutant plasmid by introducing point mutations into the miR-181b binding site in the PDCD4 3′-UTR to eliminate miR-181b binding ability. The mutated luciferase reporter was not affected by miR-181b overexpression or knockdown (Fig. 3E). These results suggest that the binding site strongly contributes to the miRNA-mRNA interaction.
It has been previously reported that the CRC-related transcription factor STAT3 (Morikawa et al., 2011; Pradhan et al., 2012) can activate miR-181b (Iliopoulos et al., 2010; Degagne et al., 2014). If PDCD4 is truly a miR-181b target, the alteration of STAT3 levels would simultaneously affect PDCD4 expression through miR-181b. To confirm this hypothesis, we used a STAT3 siRNA and a STAT3-specific inhibitor Stattic (Schust et al., 2006) to suppress STAT3 expression and activity, respectively, and used IL-6 to activate STAT3 activity (Iliopoulos et al., 2010). As anticipated, STAT3 siRNA and Stattic reduced miR-181b expression in CRC cells, while IL-6 treatment increased miR-181b expression (Fig. 3F). As a result, PDCD4 protein expression exhibited an inverse alteration to STAT3 (Fig. 3G and 3H).

We also excluded the possibility that STAT3 is a direct regulator of PDCD4 by measuring the mRNA level of PDCD4 after the manipulation of the level or activity of STAT3. PDCD4 mRNA levels were not affected by STAT3 siRNA, Stattic (Schust et al., 2006) and IL-6 treatment (Fig. 3I), suggesting that STAT3 might not directly inhibit PDCD4 expression at the transcriptional level.

**miR-181b promotes CRC cell proliferation and migration and suppresses apoptosis by targeting PDCD4**

We hypothesized that miR-181b promotes the CRC oncogenic process by inhibiting PDCD4 expression. Thus, we investigated the effects of miR-181b-driven PDCD4 repression on CRC cell proliferation, migration and apoptosis. We first performed CCK-8 and transwell assays to analyze the effect of miR-181b on CRC cell proliferation and migration. SW480 cells transfected with miR-181b mimic exhibited increased proliferation and migration; in contrast, miR-181b inhibition had the opposite effect on cell proliferation and migration (Fig. 4A, 4C and 4D). We also investigated the effects of miR-181b on apoptosis by flow cytometric analysis. The percentage of apoptotic cells was significantly lower.
in SW480 cells transfected with miR-181b mimic and higher in cells transfected with miR-181b inhibitor compared to control cells (Fig. 4F and 4G).

However, it should be noted that transient transfection of miRNA mimics typically gives rise to supraphysiological miRNA levels in cells when the miRNA level is assessed by qRT-PCR (Thomson et al., 2013). The supraphysiological levels of transfected miRNA do not represent the functional levels, because the majority of transfected miRNA is not accessible for loading into Argonaute as functionally active miRNAs, but is actually in non-functional locations such as in lysosomes (Thomson et al., 2013). Thus, we constructed a

---

**Figure 3.** miR-181b directly regulates PDCD4 expression at the post-transcriptional level. (A) Quantitative RT-PCR analysis of miR-181b levels in SW480, Caco2 and HT-29 cells transfected with control mimic, miR-181b mimic, control inhibitor or miR-181b inhibitor. (B and C) Western blot analysis of PDCD4 protein levels in SW480, Caco2 and HT-29 cells transfected with control mimic, miR-181b mimic, control inhibitor or miR-181b inhibitor. B: representative images; C: quantitative analysis. (D) Quantitative RT-PCR analysis of PDCD4 mRNA levels in SW480, Caco2 and HT-29 cells transfected with control mimic, miR-181b mimic, control inhibitor or miR-181b inhibitor. (E) Direct binding of miR-181b to the PDCD4 3′-UTR. Firefly luciferase reporters containing the wild-type (WT) or mutant (MUT) form of human PDCD4 3′-UTR were cotransfected into SW480 cells along with control mimic, miR-181b mimic, control inhibitor or miR-181b inhibitor. At 24 h post-transfection, the cells were assayed using a luciferase assay kit. Firefly luciferase values were normalized to β-galactosidase activity and plotted as relative luciferase activity. For comparison, the luciferase activity in the control cells was set as 1. (F) Quantitative RT-PCR analysis of miR-181b levels in SW480 cells treated with control siRNA, STAT3 siRNA, DMSO, Stattic or IL-6. (G and H) Western blot analysis of PDCD4 protein levels in SW480 cells treated with control siRNA, STAT3 siRNA, DMSO, Stattic or IL-6. G: representative images; H: quantitative analysis. (I) Quantitative RT-PCR analysis of PDCD4 mRNA levels in SW480 cells treated with control siRNA, STAT3 siRNA, DMSO, Stattic or IL-6. *P < 0.05; **P < 0.01; ***P < 0.001.
Figure 4. Effects of miR-181b and PDCD4 on CRC cell proliferation, migration and apoptosis. (A) Cell proliferation assays were performed 12, 24, 36, 48, 60 and 72 h after the transfection with equal dose of control mimic, miR-181b mimic, control inhibitor or miR-181b inhibitor. (B) Cell proliferation assays were performed 12, 24, 36 and 48, 60 and 72 h after transfection with equal dose of the control mimic plus control plasmid, miR-181b mimic plus control plasmid, control mimic plus PDCD4 overexpression plasmid, or miR-181b mimic plus PDCD4 overexpression plasmid. (C–E) Transwell analysis of SW480 cells that were transfected with equal dose of control mimic, miR-181b mimic, control inhibitor or miR-181b inhibitor (upper panel), or with equal dose of control mimic plus control plasmid, miR-181b mimic plus control plasmid, control mimic plus PDCD4 overexpression plasmid, or miR-181b mimic plus PDCD4 overexpression plasmid (lower panel). C: representative images; D and E: quantitative analysis of the number of migrated cells. (F and G) Apoptosis assays were performed 24 h after transfection of SW480 cells with equal dose of control mimic, miR-181b mimic, control inhibitor or miR-181b inhibitor. F: representative images; G: quantitative analysis of the apoptotic cell ratio. **P < 0.05; ***P < 0.01; ****P < 0.001.

miR-181b targets PDCD4 in CRC
lentivirus to produce functional intracellular miR-181b via the endogenous miRNA processing pathway. As shown in Supplemental Fig. 2A, the expression levels of mature miR-181b were found to be 3–4-fold higher than the basal levels when SW480 cells were infected with miR-181b overexpression lentivirus. Such fold change is biologically and physiologically relevant, because the altered miR-181b also inhibited PDCD4 expression in SW480 cells (Fig. S2B and S2C). Furthermore, overexpression of miR-181b by lentivirus also promoted cell proliferation and migration and inhibited cell apoptosis in SW480 cells (Fig. S2D–H), to the same degree as those obtained by using miR-181b mimic. The results again verify that miR-181b regulates PDCD4 expression and consequently affects cell proliferation, migration and apoptosis.

Because a single miRNA can target hundreds of genes (Bartel, 2004), it is necessary to determine whether the effects of miR-181b on CRC cells are derived from miR-181b-mediated PDCD4 suppression. We next investigated the exact contribution of the miR-181b-PDCD4 axis on CRC cell proliferation, migration and apoptosis. We used an siRNA and an overexpression plasmid to respectively downregulate or upregulate PDCD4 protein levels. Efficient knockdown and overexpression of PDCD4 expression in SW480 cells is shown in Fig. S1A–C. As a result, PDCD4 downregulation activated proliferation and migration and suppressed apoptosis of SW480 cells, whereas PDCD4 overexpression had the opposite effect on cell proliferation, migration and apoptosis (Fig. S1D–I). Thus, miR-181b and PDCD4 have opposing effects on cell proliferation, migration and apoptosis in CRC. We subsequently investigated whether overexpression of miR-181b-resistant PDCD4 (PDCD4 ORF) was sufficient to rescue PDCD4 suppression by miR-181b and attenuated the pro-proliferation, pro-migration and anti-apoptotic effects of miR-181b on CRC cells. We transfected SW480 cells with miR-181b mimic or PDCD4 overexpression plasmid or co-transfected with miR-181b mimic and PDCD4 overexpression plasmid. As expected, cells co-transfected with the miR-181b mimic and PDCD4 overexpression plasmid showed significantly lower proliferation rates (Fig. 4B) and migration capabilities (Fig. 4C and 4E) and higher apoptosis rates (Fig. 4H and 4I) compared to cells transfected with miR-181b mimic alone. Thus, restoration of PDCD4 expression can reverse miR-181b-induced cell proliferation and migration and miR-181b-suppressed cell apoptosis, suggesting that targeting of PDCD4 is one mechanism by which miR-181b exerts its oncomiR function.

miR-181b promotes CRC growth in vivo by targeting PDCD4

Finally, we investigated the effects of miR-181b and PDCD4 on the growth of CRC xenografts in mice. We infected SW480 cells with a control lentivirus or a miR-181b overexpression lentivirus, transfected cells with a PDCD4 overexpression plasmid, or co-transfected with a miR-181b overexpression lentivirus and a PDCD4 overexpression plasmid. The effects of lentiviral infection and plasmid transfection are shown in Fig. S2A–C. Subsequently, we subcutaneously implanted the infected or transfected SW480 cells into 4-week-old nude mice. We evaluated tumor growth 30 days after cell implantation. Xenograft tumors from miR-181b-overexpressing group exhibited a significant increase in size and weight compared to the control group, whereas the sizes and weight of tumors in the group implanted with PDCD4-overexpressing cells dramatically decreased (Fig. 5A and 5B). Additionally, PDCD4 overexpression attenuated the growth-promoting effects of miR-181b (Fig. 5A and 5B), suggesting that miR-181b promotes tumor growth by silencing PDCD4. We next isolated and analyzed total RNA and protein from the tumors. Tumors from the miR-181b-overexpressing group showed a significant increase in mature miR-181b expression compared to tumors from the control group (Fig. 5C). Likewise, tumors from the miR-181b-overexpressing group expressed decreased PDCD4 protein levels compared to tumors from the control group, whereas tumors from the PDCD4-overexpressing group showed elevated PDCD4 protein levels (Fig. 5D and 5E). Moreover, tumors with both miR-181b and PDCD4 overexpression exhibited significantly higher PDCD4 levels compared to tumors overexpressing miR-181b alone (Fig. 5D and 5E), suggesting that PDCD4 overexpression rescued miR-181b-mediated PDCD4 suppression. We embed xenografted tumors in paraffin and then performed H&E staining or examined using immunohistochemical assays. H&E staining of xenograft tissues showed increased cell mitosis in the miR-181b lentivirus group and decreased mitosis in the PDCD4 plasmid group, whereas xenografts with both miR-181b and PDCD4 overexpression exhibited less cell mitosis compared to xenografts with miR-181b overexpression (Fig. 5F). Immunohistochemical staining also revealed lower PDCD4 levels in tumors from mice implanted with miR-181b-overexpressing cells, whereas tumors from the PDCD4-overexpressing mice showed increased PDCD4 protein levels (Fig. 5F and 5G). Finally, we assessed the proliferative activity of tumor cells via Ki-67 immunohistochemical staining. The percentage of Ki-67-positive tumor cells was increased in the group implanted with miR-181b lentivirus and decreased in the group implanted with PDCD4 plasmid (Fig. 5F and 5H). Likewise, PDCD4 overexpression attenuated the pro-proliferative effects of miR-181b overexpression (Fig. 5F and 5H). These results are consistent with the in vitro findings, which firmly validated the oncomiR role of miR-181b in CRC tumorigenesis through targeting of PDCD4.

DISCUSSION

Colorectal cancer is the third most common cancer worldwide. At the molecular level, colorectal cancer arises from a series of genetic and epigenetic alterations that inactivate
Figure 5. Effects of miR-181b and PDCD4 on the growth of CRC cell xenografted tumors in mice. SW480 cells were infected with a control lentivirus or a lentivirus to overexpress miR-181b, or transfected with a PDCD4 overexpression plasmid, or cotransfected with a miR-181b overexpression lentivirus and a PDCD4 overexpression plasmid. Differentially treated SW480 cells (3 × 10^6 cells per mouse) were subcutaneously implanted into 4-week-old male SCID mice (5 mice per group), and tumor growth was evaluated 30 days after cell implantation. (A) Representative images of tumors from the implanted mice. (B) Quantitative analysis of xenografted tumor weights. (C) Quantitative RT-PCR analysis of miR-181b levels in tumors from implanted mice. (D and E) Western blotting analysis of PDCD4 protein levels in tumors from implanted mice. D: representative images; E: quantitative analysis. (F–H) H&E-stained sections and immunohistochemical staining for PDCD4 and Ki-67 in tumors from implanted mice. F: representative images; G and H: quantitative analysis. *P < 0.05; **P < 0.01; ***P < 0.001.
PDCD4 is an important tumor suppressor in many cancers. In this study, we demonstrated that PDCD4 was dramatically downregulated in CRC tissues and could inhibit proliferation and migration and promote apoptosis in CRC cells and attenuate tumor growth in xenografted mice. Consistent with these results, miR-181 has also been reported to be upregulated in various human cancer types, including CRC (Nakajima et al., 2006; Xi et al., 2006; Schetter et al., 2008; Degagne et al., 2014; Liu et al., 2014), hepatocellular cancer (Wang et al., 2010a), breast cancer (Mansueto et al., 2010) and ovarian cancer (Parikh et al., 2014). During the CRC oncogenic process, miR-181 can promote tumor growth and metastasis (Ji et al., 2014) and is tightly associated with a poor prognosis (Nishimura et al., 2012) and the chemoresponse of CRC patients (Nakajima et al., 2006). Thus, it is possible that targeting of miR-181b could control CRC development and ameliorate the symptoms, as shown by other groups (Krutzel et al., 2005; Kota et al., 2009; Ma et al., 2010). More research emphasis is required to characterize the feasibility of targeting miR-181b in CRC therapy and to develop simplified and cost-effective manipulation methods.

PDCD4 is a key tumor suppressor gene and activates oncogenes. The list of classical tumor suppressors and oncogenes has been expanded to include miRNAs. Many studies have reported the extensive alteration of miRNA profiles in the initiation and developmental stages of CRC (Brunet Vega et al., 2013; Xu et al., 2016). More importantly, new studies have established the potential usefulness of miRNAs as therapeutic molecules against cancer (Kota et al., 2009; Ma et al., 2010). For example, aberrantly activated miRNAs can be silenced using antagomirs (Krutzel et al., 2005), and re-expression of miRNAs that are lost in cancers can be achieved by the induction of miRNA mimics (Kota et al., 2009). In this study, we showed that miR-181b was upregulated in CRC tissues and promoted cell proliferation and migration and suppressed cell apoptosis in vitro and accelerated tumor growth in vivo. Consistent with these results, miR-181b has also been reported to be upregulated in various human cancer types, including CRC (Nakajima et al., 2006; Xi et al., 2006; Schetter et al., 2008; Degagne et al., 2014; Liu et al., 2014), hepatocellular cancer (Wang et al., 2010a), breast cancer (Mansueto et al., 2010) and ovarian cancer (Parikh et al., 2014). During the CRC oncogenic process, miR-181 can promote tumor growth and metastasis (Ji et al., 2014) and is tightly associated with a poor prognosis (Nishimura et al., 2012) and the chemoresponse of CRC patients (Nakajima et al., 2006). Thus, it is possible that targeting of miR-181b could control CRC development and ameliorate the symptoms, as shown by other groups (Krutzel et al., 2005; Kota et al., 2009; Ma et al., 2010). More research emphasis is required to characterize the feasibility of targeting miR-181b in CRC therapy and to develop simplified and cost-effective manipulation methods.

In summary, this study identified the first time that miR-181b can target PDCD4 to promote CRC tumorigenesis. Future research on miR-181b and PDCD4 will provide us more knowledge about CRC and pave new approaches for molecular therapeutics for this disease.

MATERIALS AND METHODS

Tissue samples

CRC tissue and paired normal adjacent tissue samples were acquired from patients undergoing a surgical procedure at the Affiliated Drum Tower Hospital of Nanjing University Medical School (Nanjing, China). Both the tumor and non-tumor tissues were sent for histological analysis and diagnostic confirmation. Written consent was obtained from all patients, and all protocols concerning the use of patient samples in this study were approved by the Ethics Committee of Nanjing University. Tissue samples were immediately frozen in liquid nitrogen at the time of surgery and stored at -80°C. All experiments were performed in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) and approved guidelines of the Nanjing University. The clinical features of the patients are listed in Supplemental Table 1.

Cell culture

The SW480, Caco2 and HT29 human CRC cell lines were purchased from the Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (Shanghai, China). SW480 and HT29 cells were cultured in RPMI-1640 (Gibco, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS, Gibco) in a humidified incubator at 37°C with 5% CO₂. Caco2 cells were cultured in DMEM (Gibco) supplemented with 10% FBS (Gibco) in a humidified incubator at 37°C with 5% CO₂.
miR-181b targets PDCD4 in CRC

**RNA isolation and quantitative RT-PCR**

Total RNA was extracted from the cultured cells and human tissues using Trizol Reagent (Invitrogen, CA, USA) according to the manufacturer’s instructions. TaqMan miRNA Assay Probes (Applied Biosystems, Foster City, CA) were used to quantify mature miR-181b according to the manufacturer’s instructions. Briefly, 1 μg of total RNA was reverse-transcribed to cDNA using a stem-loop RT primer (Applied Biosystems) and AMV reverse transcriptase (TaKaRa). The reaction conditions were as follows: 16°C for 30 min, 42°C for 30 min and 85°C for 5 min. Quantitative real-time PCR was performed using a TaqMan PCR kit on an Applied Biosystems 7500 Sequence Detection System (Applied Biosystems). The reactions were incubated in a 96-well optical plate at 95°C for 5 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. All of the reactions were run in triplicate. After the reactions were complete, the cycle threshold (CT) data were determined using fixed threshold settings, and the mean CT was determined from triplicate PCRs. A comparative CT method was used to compare each condition to the control reactions. U6 snRNA was used as an internal control, and the relative amount of miRNA normalized to U6 was calculated with the equation 2^([ΔΔCT]) in which ΔΔCT = (CT miR-181b − CT U6)control − (CT miR-181b − CT U6)target.

To quantify PDCD4 and GAPDH mRNA, 1 μg of total RNA was reverse transcribed to cDNA using Oligo d(T)18 primers (TaKaRa) and AMV reverse transcriptase (TaKaRa). The reaction conditions were as follows: 42°C for 60 min and 85°C for 5 min. Real-time PCR was performed using the RT product, SYBR Green dye (Invitrogen) and specific primers for PDCD4 and GAPDH. The primer sequences were as follows: PDCD4 (sense): GTTGGCAGATCTCCTAGCATGG; PDCD4 (antisense): TCCACATCAGTTGTGCTCATTAC; GAPDH (sense): CGAGCCACATCGCTCAGACA; and GAPDH (antisense): GTGGTGAAGACGCCAGTGGA. The reactions were incubated at 95°C for 5 min, followed by 40 cycles of 95°C for 15 s and 60°C for 30 s. After the reactions were complete, the Ct values were determined by setting a fixed threshold. The relative amounts of PDCD4 mRNAs were normalized to GAPDH using a similar method as described above.

**Protein isolation and western blot**

Cells or tissues were lysed in RIPA lysis buffer (Beyotime, Shanghai, China) with freshly added PMSF (Beyotime, Shanghai, China) for 30 min on ice and were centrifuged at 12,000 × g at 4°C for 10 min. The supernatant was collected, and the protein concentration was calculated using a BCA protein assay kit (Thermo Scientific, Rockford, IL, USA). Proteins were separated by SDS-PAGE (Bio-Rad). After electrophoresis, the proteins were electrotransferred to PVDF membranes (Roche) and then blocked with 5% skim milk for 1 h. The membranes were then incubated with primary antibodies at 4°C overnight. After 4 washes (10 min each) in TBST, the membranes were incubated with horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature. After 4 washes (10 min each), the membranes were incubated with Pierce SuperSignal West Pico chemiluminescence substrate (Thermo). The same membrane was also probed with a GAPDH antibody as a control. Antibodies against PDCD4 and GAPDH were purchased from Santa Cruz Biotechnology (sc-130545 and sc-25778, Santa Cruz, CA, USA).

miR-181b overexpression and knockdown

miR-181b overexpression was achieved by transfecting CRC cells with a miR-181b mimic, a synthetic double-stranded RNA oligonucleotide mimicking the miR-181b precursor. miR-181b knockdown was achieved by transfecting CRC cells with miR-181b inhibitor, a chemically modified antisense oligonucleotide designed to target mature miR-181b. Synthetic miR-181b mimic and inhibitor and scrambled negative control RNAs (control mimic and inhibitor) were purchased from GenePharma (Shanghai, China). SW480, Caco2 and HT29 cells were seeded in 6-well plates and transfected using Lipofectamine 2000 (Invitrogen) on the following day when the cells were approximately 60%–80% confluent. For miR-181b overexpression experiments, 200 pmol of miR-181b mimic or control mimic were added to each well. For miR-181b knockdown experiments, 200 pmol of miR-181b inhibitor or control inhibitor were added to each well. At 6 h after transfection, the SW480 and HT29 cell medium was changed to RPMI-1640 supplemented with 2% FBS and the Caco2 cell medium was changed to DMEM supplemented with 2% FBS. The cells were harvested 48 h after transfection for total RNA or protein isolation.

**Plasmid construction and siRNA interference assay**

Mammalian expression plasmids designed to specifically express the full-length open reading frame (ORF) of the human PDCD4 gene were purchased from Genescript (Nanjing, China). An empty plasmid served as a negative control (control plasmid). siRNAs designed to specifically silence PDCD4 or STAT3 were purchased from GenePharma (Shanghai, China). A scrambled siRNA served as a control. The siRNA sequences were as follows: si-PDCD4: GCGGAAUUUGUUAAAGAGAUU; si-STAT3: CACCAUUUGGUGUULCAUU. The overexpression plasmids and siRNAs were transfected into CRC cells using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. Total RNA and protein were isolated 48 h after transfection and were assessed by quantitative RT-PCR and western blot, respectively.

**STAT3 activation and inhibition**

To activate STAT3, recombinant human IL-6 (200-06, PeproTech) was added to CRC cells at a final concentration of 80 ng/mL. To suppress STAT3 activity or expression, a STAT3-specific inhibitor Static (S7947, Sigma) or an siRNA against STAT3 (sequence described above) was added to CRC cells.

Luciferase reporter assay

A 378-bp fragment of the PDCD4 3′-UTR containing the presumed miR-181b binding site was amplified by PCR with human genomic DNA as a template. The following set of primers (with restriction enzyme cut site and protection bases in the 5′ end) was used: GGACTAGTCCCATCAGCGTCGCTTGAATA (forward primer) and GGACTAGTCCCATCAGCGTCGCTTGAATA (reverse primer). The 378-bp fragment is located in the last exon of PDCD4. The two additional sequences GGACTAGTCCCATCAGCGTCGCTTGAATA in each primer were specially added for restriction enzyme Spe I and Hind III, respectively. The PCR fragment was digested with Spe I and Hind III restriction enzyme and then inserted into the Spe I-Hind III sites of
the pMiR-REPORT plasmid (Ambion, USA). Successful insertion was confirmed by DNA sequencing. To test binding specificity, sequences that interacted with the miR-181b seed sequence were mutated from GAATGT to CCTACA, and the synthetic PDCD4 3'-UTR mutant fragment was inserted into an equivalent reporter plasmid. For the luciferase reporter assays, SW480 cells were cultured in 24-well plates, and each well was co-transfected with 0.2 µg of firefly luciferase reporter plasmid, 0.2 µg of β-galactosidase (β-gal) expression plasmid (Ambion), and equal amounts (50 pmol) of miR-181b mimic, miR-181b inhibitor or the scrambled negative control RNAs using Lipofectamine 2000 (Invitrogen). The β-gal plasmid was used as a transfection efficiency control. The cells were assayed using a luciferase assay kit 24 h post-transfection (Promega, Madison, WI, USA).

**Cell proliferation assay**

SW480 cells were plated at 2 × 10^4 cells per well in 96-well plates and incubated overnight in RPMI-1640 supplemented with 10% FBS. The cell proliferation index was measured using the Cell Counting Kit-8 (CCK-8, Dojindo, Japan) at 12, 24, 36, 48, 60 and 72 h post-transfection according to the manufacturer's instruction. Absorbance was measured at a wavelength of 450 nm. All experiments were performed in triplicate.

**Cell migration assay**

Cell migration assays were performed using Millipore 24-Well Millipore plates containing an 8-µm pore membrane. The bottom face of the membrane was coated with 1% gelatin. Cells were harvested 24 h after transfection and suspended in FBS-free RPMI-1640 culture medium. The cells were then added to the upper chamber (2 × 10^6 cells/well) and 0.5 mL RPMI-1640 plus 20% FBS was added to the lower compartment. The Transwell-containing plates were incubated for 24 h in the incubator. After incubation, cells that had entered the lower surface of the filter membrane were fixed with 4% paraformaldehyde for 25 min at room temperature. The membrane was washed 3 times with distilled water and stained with 0.1% crystal violet in methanol for 15 min at room temperature. Cells remaining on the upper surface of the filter membrane (non-migrant) were gently scraped off with a cotton swab. The lower surfaces (with migrant cells) were captured by photomicroscopy (BX51 Olympus, Japan), and the cells were blindly counted (five fields per chamber).

**Cell apoptosis assay**

SW480 cell apoptosis was tested using an Annexin V-FITC/propidium iodide (PI) staining assay. SW480 cells were cultured in 6-well plates and transfected with the above-mentioned RNAs or plasmids. To induce apoptosis, LPS (Sigma) was added to a concentration of 400 ng/mL. The cells were harvested after culturing for 24 h in FBS-depleted medium. Flow cytometric analysis of apoptotic cells was performed using an Annexin V-FITC/PI staining kit (BD Biosciences, San Jose, CA, USA). After washing with cold PBS, the cells were resuspended in binding buffer (100 mmol/L HEPES, pH 7.4; 100 mmol/L NaCl; and 25 mmol/L CaCl2), followed by staining with Annexin V-FITC/PI at room temperature in the dark for 15 min. Apoptotic cells were then evaluated by gating the PI- and Annexin V-positive cells using a fluorescence-activated cell-sorting (FACS) flow cytometer (BD Biosciences, San Jose, CA, USA). All experiments were performed in triplicate.

**Establishment of tumor xenografts in mice**

4-week-old male SCID (severe combined immune deficiency) mice (nu/nu) were purchased from the Model Animal Research Center of Nanjing University (Nanjing, China) and maintained under specific pathogen-free conditions at Nanjing University. A 300-bp fragment containing the miR-181b genomic sequence was obtained by PCR amplification of human DNA and cloned into a lentiviral expression vector. SW480 cells were infected with a control lentivirus or a miR-181b overexpression lentivirus, transfected with a PDCD4 overexpression plasmid, or co-transfected with a miR-181b overexpression lentivirus and a PDCD4 overexpression plasmid. After infection and/or transfection, SW480 cells were subcutaneously injected into SCID mice (3 × 10^6 cells in 0.2 mL PBS per mouse, 5 mice per group). The needle was inserted into the left side of the amput, midway down, 5 mm deep at a 45° angle. Mice were sacrificed 30 days after injection to remove the xenografted tumors, and the weights of mice and tumors were measured. A portion of the tissues was used for protein and total RNA extraction, and the remaining tissue was fixed in 4% paraformaldehyde for 24 h. The tissue was processed for Hematoxylin and Eosin (H&E) staining or immunohistochemical staining for PDCD4 and Ki-67. All experiments were approved by the Institutional Review Board of Nanjing University (Nanjing, China) and performed in accordance with the U.K. Animals (Scientific Procedures) Act (1986) and the guidelines of the National Institutes.

**Statistical analysis**

All of the images of western blot assay and migration assay were representative of at least three independent experiments. Quantitative RT-PCR assay, luciferase reporter assay, proliferation assay and apoptosis assay were performed in triplicate, and each individual experiment was repeated several times. The results are presented as the means ±SE of at least three independent experiments. Observed differences were considered statistically significant at P < 0.05 using Student’s t-test.

**ACKNOWLEDGEMENTS**

This work was supported by grants from the National Natural Science Foundation of China (Grant No. 31271378 and 81302197) and the Changzhou High-Level Medical Talents Training Project (No. 2016CZBJ006).

**ABBREVIATIONS**

CRC, Colorectal cancer; miRNA, microRNA; PDCD4, Programmed cell death 4.

**COMPLIANCE WITH ETHICS GUIDELINES**

Yanqing Liu, Uzair-ur-Rehman, Yu Guo, Hongwei Liang, Rongjie Cheng, Fei Yang, Yeting Hong, Chihao Zhao, Minghui Liu,
Mengchao Yu, Xinyan Zhou, Kai Yin, Jiangning Chen, Junfeng Zhang, Chenyu Zhang, Feng Zhi and Xi Chen declare that they have no conflict of interest. All procedures followed were in accordance with the ethical standards of the Ethics Committee of Nanjing University on human experimentation and with the Helsinki Declaration of 1975, as revised in 2000 (5). Informed consent was obtained from all patients for being included in the study. All the Ethics Committee of Nanjing University guidelines for the care and use of laboratory animals were followed.

OPEN ACCESS

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

REFERENCES

Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281–297

Biyane A, Singh P, Klempnauer KH (2015) Translation, Pdcd4 and elf4A. Oncosience 2:731–732

Brunet Vega A, Pericay C, Moya I, Ferrer A, Dotor E, Pisa A, Casalots A, Serra-Aracil X, Oliva JC, Ruiz A et al (2013) microRNA expression profile in stage III colorectal cancer: circulating miR-18a and miR-29a as promising biomarkers. Oncol Rep 30:320–326

Bushell N, Cohen SM (2007) microRNA functions. Annu Rev Cell Dev Biol 23:175–205

Chen Y, Knose T, Kristiansen G, Pietas A, Garber ME, Matsuhashi S, Ozaki I, Petersen I (2003) Loss of PDCC4 expression in human lung cancer correlates with tumour progression and prognosis. J Pathol 200:640–646

Degagne E, Pandurangan A, Bandhuvula P, Kumar A, Eltanawy A, Zhang M, Yoshinaga Y, Nefedov M, de Jong PJ, Fong LG et al (2014) Sphingosine-1-phosphate lyase downregulation promotes colon carcinogenesis through STAT3-activated microRNAs. J Clin Invest 124:5368–5384

Dow LE, O’Rourke KP, Simon J, Tschaharganeh DF, van Es JH, Clevers H, Lowe SW (2015) Apc restoration promotes cellular differentiation and reestablishes crypt homeostasis in colorectal cancer. Cell 161:1539–1552

Downward J (2003) Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3:11–22

Esquela-Kerscher A, Slack FJ (2006) Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer 6:259–269

Gonzalez-Villasana V, Nieves-Alicea R, McMurtry V, Gutierrez-Puente Y, Tari AM (2012) Programmed cell death 4 inhibits leptin-induced breast cancer cell invasion. Oncol Rep 27:861–866

Guo PT, Yang D, Sun Z, Xu HM (2013) PDCD4 functions as a suppressor for pT2a and pT2b stage gastric cancer. Oncol Rep 29:1007–1012

He L, Hannon GJ (2004) MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5:522–531

Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K (2010) STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell 39:493–506

Ji D, Chen Z, Li M, Zhan T, Yao Y, Zhang Z, Xi J, Yan L, Gu J (2014) MicroRNA-181a promotes tumor growth and liver metastasis in colorectal cancer by targeting the tumor suppressor WIF-1. Mol Cancer 13:86

Ji J, Yamashita T, Budhu A, Forgues M, Jia HL, Li C, Deng C, Wauthier E, Reid LM, Ye QH et al (2009) Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology 50:472–480

Kota J, Chivukula RR, O’Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, Chang TC, Vivekanandan P, Torbenson M, Clark KR et al (2009) Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137:1005–1017

Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschi T, Mancherman M, Stoffel M (2005) Silencing of microRNAs in vivo with ‘antisomiRs’. Nature 438:685–689

Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, Pfeffer S, Rice A, Kamphorst AO, Landthaler M et al (2007) A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 129:1401–1414

Li X, Xin S, He Z, Che X, Wang J, Xiao X, Chen J, Song X (2014) MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor PDCD4 and promotes cell transformation, proliferation, and metastasis in renal cell carcinoma. Cell Physiol Biochem 33:1631–1642

Liu J, Shi W, Wu C, Ju J, Jiang J (2014) miR-181b as a key regulator of the oncogenic process and its clinical implications in cancer (Review). Biomed Rep 2:7–11

Luo Y, Tsuchiya KD, Il Park D, Fausel R, Kann gum S, Welsh P, Dzieciatkowski S, Wang J, Grady WM (2013) RET is a potential tumor suppressor gene in colorectal cancer. Oncogene 32:2037–2047

Ma L, Reinhardt F, Pan E, Soutschek J, Bhat B, Marcussen EG, Teruya-Feldstein J, Bell GW, Weinberg RA (2010) Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol 28:341–347

Mansueto G, Forzati F, Ferraro A, Pallante P, Bianco M, Esposito F, Iaccarino A, Troncone G, Fusco A (2010) Identification of a new pathway for tumor progression: MicroRNA-181b up-regulation and CBX7 down-regulation by HMGA1 protein. Genes Cancer 1:210–224

Morikawa T, Baba Y, Yamauchi M, Kuchiba A, Nosho K, Shima K, Tanaka N, Huttenhower C, Frank DA, Fuchs CS et al (2011) STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers. Clin Cancer Res 17:1452–1462

Nakajima G, Hayashi K, Xi Y, Kudo K, Uchida K, Takasaki K, Yamamoto M, Ju J (2006) Non-coding MicroRNAs hsa-let-7g and hsa-miR-181b are Associated with chemoresponse to S-1 in colon cancer. Cancer Genom Proteom 3:317–324

© The Author(s) 2016. This article is published with open access at Springerlink.com and journal.hep.com.cn 733
Nishimura J, Handa R, Yamamoto H, Tanaka F, Shibata K, Mimori K, Takemasa I, Mizushima T, Ikeda M, Sekimoto M et al (2012) microRNA-181a is associated with poor prognosis of colorectal cancer. Oncol Rep 28:2221–2226

Parikh A, Lee C, Joseph P, Marchini S, Baccarini A, Kolev V, Romualdi C, Fruscio R, Shah H, Wang F et al (2014) microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition. Nat Commun 5:2977

Pradhan MP, Prasad NK, Palakal MJ (2012) A systems biology approach to the global analysis of transcription factors in colorectal cancer. BMC Cancer 12:331

Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen ST, Kwong DL, Au GK et al (2008) MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299:425–436

Schust J, Sperl B, Hollis A, Mayer TU, Berg T (2006) Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol 13:1235–1242

Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65:5–29

Singh P, Wedeken L, Waters LC, Carr MD, Klemptnauer KH (2011) Pdcd4 directly binds the coding region of c-myb mRNA and suppresses its translation. Oncogene 30:4864–4873

Su J, Liang H, Yao W, Wang N, Zhang S, Yan X, Feng H, Pang W, Wang Y, Wang X et al (2014) MiR-143 and MiR-145 regulate IGF1R to suppress cell proliferation in colorectal cancer. PLoS One 9:e114420

Thomson DW, Bracken CP, Szubert JM, Goodall GJ (2013) On measuring microRNAs after transient transfection of mimics or antisense inhibitors. PLoS One 8:e55214

Waldner MJ, Foersch S, Neurath MF (2012) Interleukin-6—a key regulator of colorectal cancer development. Int J Biol Sci 8:1248–1253

Wang B, Hsu SH, Majumder S, Kutay H, Huang W, Jacob ST, Ghoshal K (2010a) TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene 29:1787–1797

Wang L, Zhao M, Guo C, Wang G, Zhu F, Wang J, Wang X, Wang Q, Zhao W, Shi Y et al (2016) PDCD4 deficiency aggravates colitis and colitis-associated colorectal cancer via promoting IL-6/STAT3 pathway in mice. Inflamm Bowel Dis 22(5):1107–1118

Wang WQ, Zhang H, Wang HB, Sun YG, Peng ZH, Zhou G, Yang SM, Wang RQ, Fang DC (2010b) Programmed cell death 4 (PDCD4) enhances the sensitivity of gastric cancer cells to TRAIL-induced apoptosis by inhibiting the PI3K/Akt signaling pathway. Mol Diagn Ther 14:155–161

Wedeken L, Singh P, Klemptnauer KH (2011) Tumor suppressor protein Pdcd4 inhibits translation of p53 mRNA. J Biol Chem 286:42855–42862

Xi Y, Formentini A, Chien M, Weir DB, Russo JJ, Ju J, Kornmann M, Ju J (2006) Prognostic Values of microRNAs in Colorectal Cancer. Biomark Insights 2:113–121

Xu P, Zhu Y, Sun B, Xiao Z (2016) Colorectal cancer characterization and therapeutic target prediction based on microRNA expression profile. Sci Rep 6:20616

Yang HS, Cho MH, Zakowicz H, Hegamyer G, Sonenberg N, Colburn NH (2004) A novel function of the MA-3 domains in transformation and translation suppressor Pdcd4 is essential for its binding to eukaryotic translation initiation factor 4A. Mol Cell Biol 24:3894–3906

Yang HS, Jansen AP, Komar AA, Zheng X, Merrick WC, Costes S, Lockett SJ, Sonenberg N, Colburn NH (2003) The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. Mol Cell Biol 23:26–37

Yang HS, Matthews CP, Clair T, Wang Q, Baker AR, Li CC, Tan TH, Colburn NH (2006) Tumorigenesis suppressor Pdcd4 down-regulates mitogen-activated protein kinase kinase kinase kinase 1 expression to suppress colon carcinoma cell invasion. Mol Cell Biol 26:1297–1306

Yang M, Liu R, Li X, Liao J, Pu Y, Pan E, Yin L, Wang Y (2014) miRNA-183 suppresses apoptosis and promotes proliferation in esophageal cancer by targeting PDCD4. Mol Cells 37:873–880

Zhao LD, Zheng WW, Wang GX, Kang XC, Qin L, Ji JJ, Hao S (2016) Epigenetic silencing of miR-181b contributes to tumorigenicity in colorectal cancer by targeting RASSF1A. Int J Oncol 48:1977–1984